Pfizer to Present 45 Oncology Abstracts at ESMO 2026
NEW YORK — September 28, 2026 Pfizer Inc. announced that it will present data from 45 company-sponsored, investigator-sponsored and...
Padcev
Advertisement
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Advertisements
Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
KEYTRUDA Plus Padcev Extends Survival in MIBC Trial
RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...
FDA Clears New KEYTRUDA Regimens for Bladder Cancer Care
Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...
Advertisement
